Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 1/2024

Open Access 21-10-2023 | Anticoagulant | Systematic Review

Prevalence of and Risk Factors for Drug-Related Readmissions in Older Adults: A Systematic Review and Meta-Analysis

Authors: Narisha Prasad, Edward C. Y. Lau, Ilsa Wojt, Jonathan Penm, Zhaoli Dai, Edwin C. K. Tan

Published in: Drugs & Aging | Issue 1/2024

Login to get access

Abstract

Background

Older adults are at an increased risk of drug-related problems, especially following discharge from hospital. Drug-related readmissions place a large burden on the patient and the healthcare system. However, previous studies report inconsistent results on the prevalence and associated risk factors for drug-related hospital readmissions in older adults.

Objectives

We aimed to assess the prevalence of drug-related readmissions in older adults aged 65 years and older and investigate the drug classes, preventability and risk factors most associated with these readmissions.

Methods

A systematic review and meta-analysis were undertaken to answer our objectives. A search of four databases (MEDLINE, Embase, CINAHL and Scopus) was conducted. Three authors independently performed title and abstract screening, full-text screening and data extraction of all included studies. A meta-analysis was conducted to calculate the pooled prevalence of drug-related readmissions across all studies, and a subgroup analysis was performed to explore heterogeneity among studies reporting on adverse drug reaction-related readmissions.

Results

A total of 1978 studies were identified in the initial search, of which four studies were included in the final synthesis. Three studies focused on readmissions due to adverse drug reactions and one study focused on readmissions due to drug-related problems. A pooled prevalence of 9% (95% confidence interval 2–18) was found for drug-related readmissions across all studies, and a pooled prevalence of 6% (95% confidence interval 4–10) was found for adverse drug reaction-related readmissions. Three studies explored the preventability of readmissions and 15.4–22.2% of cases were deemed preventable. The drug classes most associated with adverse drug reaction readmissions included anticoagulants, antibiotics, psychotropics and chemotherapy agents. Polypharmacy (the use of five or more medications) and several comorbidities such as cancer, liver disease, ischaemic heart disease and peptic ulcer disease were identified as risk factors for drug-related readmissions.

Conclusions

Almost one in ten older adults discharged from hospital experienced a drug-related hospital readmission, with one fifth of these deemed preventable. Several comorbidities and the use of polypharmacy and high-risk drugs were identified as prominent risk factors for readmission. Further research is needed to explore possible causes of drug-related readmissions in older adults for a more guided approach to the development of effective medication management interventions.
Appendix
Available only for authorised users
Literature
1.
Kanasi E, Ayilavarapu S, Jones J. The aging population: demographics and the biology of aging. Periodontol 2000. 2016;72(1):13–8.PubMedCrossRef
2.
Aidoud A, Gana W, Poitau F, Debacq C, Leroy V, Nkodo JA, et al. High prevalence of geriatric conditions among older adults with cardiovascular disease. J Am Heart Assoc. 2023;12(2): e026850.PubMedPubMedCentralCrossRef
3.
Sinclair AJ, Abdelhafiz AH. Multimorbidity, frailty and diabetes in older people-identifying interrelationships and outcomes. J Pers Med. 2022;12(11):1911.PubMedPubMedCentralCrossRef
4.
Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021;12(3):463–73.PubMedPubMedCentralCrossRef
5.
Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96.PubMedCrossRef
6.
Hsu HF, Chen KM, Belcastro F, Chen YF. Polypharmacy and pattern of medication use in community-dwelling older adults: a systematic review. J Clin Nurs. 2021;30(7–8):918–28.PubMedCrossRef
7.
Garcia-Caballos M, Ramos-Diaz F, Jimenez-Moleon JJ, Bueno-Cavanillas A. Drug-related problems in older people after hospital discharge and interventions to reduce them. Age Ageing. 2010;39(4):430–8.PubMedCrossRef
8.
Plácido AI, Herdeiro MT, Morgado M, Figueiras A, Roque F. Drug-related problems in home-dwelling older adults: a systematic review. Clin Ther. 2020;42(4):559-72.e14.PubMedCrossRef
9.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.PubMedCrossRef
10.
Chiatti C, Bustacchini S, Furneri G, Mantovani L, Cristiani M, Misuraca C, et al. The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people. Drug Saf. 2012;35(1):73–87.PubMedCrossRef
11.
Alqenae FA, Steinke D, Keers RN. Prevalence and nature of medication errors and medication-related harm following discharge from hospital to community settings: a systematic review. Drug Saf. 2020;43(6):517–37.PubMedPubMedCentralCrossRef
12.
Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR. Hospitalization in older patients due to adverse drug reactions: the need for a prediction tool. Clin Interv Aging. 2016;11:497–505.PubMedPubMedCentralCrossRef
13.
Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012;35(1):29–45.PubMedCrossRef
14.
Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE. Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39(9):847–57.PubMedCrossRef
15.
El Morabet N, Uitvlugt EB, Bemt BJF, Bemt P, Janssen MJA, Karapinar-Carkit F. Prevalence and preventability of drug-related hospital readmissions: a systematic review. J Am Geriatr Soc. 2018;66(3):602–8.PubMedCrossRef
16.
Linkens AEMJH, Milosevic V, van der Kuy PHM, Damen-Hendriks VH, Mestres Gonzalvo C, Hurkens KPGM. Medication-related hospital admissions and readmissions in older patients: an overview of literature. Int J Clin Pharm. 2020;42(5):1243–51.
17.
Ruiz-Ramos J, Juanes-Borrego A, Puig-Campany M, Blazquez-Andión M, López-Vinardell L, Gilabert-Perramon A, et al. Cost-effectiveness analysis of implementing a secondary prevention programme in those patients who visited an emergency department for drug-related problems. Int J Pharm Pract. 2022;30(5):434–40.PubMedCrossRef
18.
Wright EA, Graham JH, Maeng D, Tusing L, Zaleski L, Martin R, et al. Reductions in 30-day readmission, mortality, and costs with inpatient-to-community pharmacist follow-up. J Am Pharm Assoc. 2019;59(2):178–86.CrossRef
19.
20.
Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795–801.PubMedCrossRef
21.
Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Inern Med. 2008;168(17):1890–6.
22.
23.
Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, et al. Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years. Eur J Clin Pharmacol. 2016;72(5):631–9.PubMedCrossRef
24.
Kempen TGH, Hedman AN, Hadziosmanovic N, Lindner KJ, Melhus H, Nielsen EI, et al. Risk factors for and preventability of drug-related hospital revisits in older patients: a post-hoc analysis of a randomized clinical trial. Br J Clin Pharmacol. 2023;89(5):1575–87.PubMedCrossRef
25.
Ekerstad N, Bylin K, Karlson BW. Early rehospitalizations of frail elderly patients: the role of medications: a clinical, prospective, observational trial. Drug Healthc Patient Saf. 2017;9:77–88.PubMedPubMedCentralCrossRef
26.
Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK: incidence and cost of medication harm in older adults. Br J Clin Pharmacol. 2018;84(8):1789–97.PubMedPubMedCentralCrossRef
27.
Hallas J, Harvald B, Gram LF, Grodum E, Brøsen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228(2):83–90.PubMedCrossRef
28.
Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12(4):280–5.PubMedPubMedCentralCrossRef
29.
Olivier P, Caron J, Haramburu F, Imbs J-L, Jonville-Béra A-P, Lagier G, et al. Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale. Therapie. 2005;60(1):39–45.PubMedCrossRef
30.
Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults: a tolerability perspective. Drugs Aging. 1997;10(1):34–49.PubMedCrossRef
31.
García-Pérez L, Linertová R, Lorenzo-Riera A, Vázquez-Díaz JR, Duque-González B, Sarría-Santamera A. Risk factors for hospital readmissions in elderly patients: a systematic review. QJM. 2011;104(8):639–51.PubMedCrossRef
32.
33.
34.
Wojt IR, Cairns R, Gillooly I, Patanwala AE, Tan ECK. Clinical factors associated with increased length of stay and readmission in patients with medication-related hospital admissions: a retrospective study. Res Soc Admin Pharm. 2022;18(7):3184–90.CrossRef
35.
Ćurković M, Dodig-Ćurković K, Erić AP, Kralik K, Pivac N. Psychotropic medications in older adults: a review. Psychiatr Danub. 2016;28(1):13–24.PubMed
36.
Parks ALMD, Fang MCMDMPH. Anticoagulation in older adults with multimorbidity. Clin Geriatr Med. 2016;32(2):331–46.
37.
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–52.PubMedPubMedCentralCrossRef
38.
39.
Kurczewska-Michalak M, Lewek P, Jankowska-Polańska B, Giardini A, Granata N, Maffoni M, et al. Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol. 2021;12: 734045.PubMedPubMedCentralCrossRef
40.
Verma A, Saha S, Jarl J, Conlon E, McGuinness B, Trépel D. An overview of systematic reviews and meta-analyses on the effect of medication interventions targeting polypharmacy for frail older adults. J Clin Med. 2023;12(4):1379.PubMedPubMedCentralCrossRef
41.
Liebzeit D, Rutkowski R, Arbaje AI, Fields B, Werner NE. A scoping review of interventions for older adults transitioning from hospital to home. J Am Geriatr Soc. 2021;69(10):2950–62.PubMedPubMedCentralCrossRef
42.
Ozavci G, Bucknall T, Woodward-Kron R, Hughes C, Jorm C, Joseph K, et al. A systematic review of older patients’ experiences and perceptions of communication about managing medication across transitions of care. Res Soc Admin Pharma. 2021;17(2):273–91.CrossRef
43.
Lee JY, Yang YS, Cho E. Transitional care from hospital to home for frail older adults: a systematic review and meta-analysis. Geriatr Nurs. 2022;43:64–76.PubMedCrossRef
44.
İlkin N. Preventable hospitalizations in older adults: a dream or reality? İstanbul Med J. 2017;18(3):114–9.CrossRef
45.
Villeneuve Y, Courtemanche F, Firoozi F, Gilbert S, Desbiens M-P, Desjardins A, et al. Impact of pharmacist interventions during transition of care in older adults to reduce the use of healthcare services: a scoping review. Res Soc Admin Pharm. 2021;17(8):1361–72.CrossRef
46.
Riordan DO, Walsh KA, Galvin R, Sinnott C, Kearney PM, Byrne S. The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: a systematic review. SAGE Open Med. 2016;4:2050312116652568.PubMedPubMedCentralCrossRef
47.
Uchida M, Suzuki S, Sugawara H, Suga Y, Nakagawa T, Takase H. Multicentre prospective observational study on community pharmacist interventions to reduce inappropriate medications. Int J Pharm Pract. 2022;30(5):427–33.PubMedCrossRef
48.
Quan H, Li B, Duncan Saunders L, Parsons GA, Nilsson CI, Alibhai A, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database: assessing validity of ICD-9-CM and ICD-10. Health Serv Res. 2008;43(4):1424–41.PubMedPubMedCentralCrossRef
Metadata
Title
Prevalence of and Risk Factors for Drug-Related Readmissions in Older Adults: A Systematic Review and Meta-Analysis
Authors
Narisha Prasad
Edward C. Y. Lau
Ilsa Wojt
Jonathan Penm
Zhaoli Dai
Edwin C. K. Tan
Publication date
21-10-2023
Publisher
Springer International Publishing
Keyword
Anticoagulant
Published in
Drugs & Aging / Issue 1/2024
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-023-01076-8

Other articles of this Issue 1/2024

Drugs & Aging 1/2024 Go to the issue

Original Research Article

Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross-sectional study

Original Research Article

Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial

Letter to the Editor

Authors’ Reply to Langford et al.: “Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing”

Original Research Article

Do Proton Pump Inhibitors Reduce Upper Gastrointestinal Bleeding in Older Patients with Atrial Fibrillation Treated with Oral Anticoagulants? A Nationwide Cohort Study in France

Systematic Review

Potentially inappropriate prescribing in multimorbid and polymedicated older adults with AF: A Systematic Review and Meta-Analysis

Letter to the Editor

Comment on: “Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits